Molecular typing relies on molecular genetic screening and isn't yet routinely out there. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 could be practical, https://wayneu641lsy7.izrablog.com/profile